The Story of a Medical Specialist Who Puts Her Life on the Line in Conflict Zones. Driven solely by her vocation as a doctor, ...
Toray's asset TRK-950 is a monoclonal antibody targeting Caprin-1 that is in Phase 2 development for Gastric cancer, providing validation for this antigen as a promising ISAC target. The connection ...
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company ...
Multiple programmed cell death patterns predict the prognosis and drug sensitivity in gastric cancer
Department of General Surgery, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China Background: Gastric cancer (GC ...
Patients with gastroesophageal junction and gastric cancer participating in the DisTinGuish mid-stage phase 2 trial took sirexatamab in combination with tislelizumab, a BeiGene therapy.
Leap Therapeutics, Inc.'s DKN-01 showed disappointing results in the DisTinGuish trial for gastric and gastroesophageal junction cancer. The DeFianCe trial in colorectal cancer was closer to ...
Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1 ...
What is stenosis after gastric bypass surgery? After gastric bypass surgery for weight loss, the new connection between the stomach pouch and the small intestine may narrow. This is called an ...
Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback